Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection

Blood

Volumn 117, Issue 21, 2011, Pages 5582-5590

  Corbeau, Pierre ^a,b,c   Reynes, Jacques ^c,d,e  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

^c UNIV MONTPELLIER   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CHEMOKINE RECEPTOR CCR5; CORTICOSTEROID; CYCLOSPORIN A; FAS ANTIGEN; FAS LIGAND; GROWTH HORMONE; HYDROXYUREA; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; MARAVIROC; MYCOPHENOLIC ACID; RALTEGRAVIR; RAPAMYCIN; TACROLIMUS; TENOFOVIR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VALGANCICLOVIR;

AGE; APOPTOSIS; CANCER GROWTH; CARPAL TUNNEL SYNDROME; CD4+ T LYMPHOCYTE; DRUG MEGADOSE; GENDER; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERGLYCEMIA; IMMUNE RECONSTITUTION; IMMUNE RESPONSE; LYMPHOCYTOPENIA; LYMPHOPOIESIS; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENESCENCE; THYMUS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 79957617692     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-322453     Document Type: Review

References (110)

1. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virological suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO Trial. Clin Infect Dis. 2009;49(9):1441-1449.
2. Lewden C, Chêne G, Morlat P, et al. HIV-infected adults with a CD4 count grater than 500 cells/ mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46(1):72-77. (Pubitemid 47514615)
3. Nicastri E, Chiesi A, Angeletti C, et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol. 2005;76(2):153-160. (Pubitemid 40593998)
4. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(5):553-558. (Pubitemid 351442024)
5. Gutiérrez F, Padilla S, Masia M, et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res. 2008;6(2):100-107. (Pubitemid 351479789)
6. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
7. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS. 2010;24(4):614-617.
8. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS. 2003;17(7):963-969. (Pubitemid 36549707)
9. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364(9428):51-62.
10. Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2002;185(4):471-480. (Pubitemid 34142809)
11. Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment. J Acquir Immune Defic Syndr. 2006;43(4):433-435. (Pubitemid 44737100)
12. Autran B, Carcelaint G, Li TS, et al. Restoration of the immune system with anti-retroviral therapy. Immunol Lett. 1999;66(1-3):207-211. (Pubitemid 29136840)
13. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103(10):1391-1398. (Pubitemid 29535495)
14. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163(18):2187-2195. (Pubitemid 37248783)
15. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197(1):126-133. (Pubitemid 351263476)
16. Lok JJ, Bosch RJ, Benson CA, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS. 2010;24(12):1867-1876.
17. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000;14(17):2635-2642. (Pubitemid 32118716)
18. Tsukamoto H, Clise-Dwyer K, Huston GE, et al. Age-associated increase on lifespan of naîve CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc Natl Acad Sci U S A. 2009;106(43):18333-18338.
19. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48(6):7878-7794.
20. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133(6):401-441.
21. Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr. 2005;40(3):288-293. (Pubitemid 41533068)
22. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12(7):745-750. (Pubitemid 28190697)
23. Marimoutou C, Chene G, Mercie P, et al. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr. 2001;27(2):161-167.
24. Chehimi J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol. 2007;179(4):2642-2650.
25. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17(14):2015-2023. (Pubitemid 37297149)
26. Della Chiara G, Fortis C, Tambussi G, Poli G. The rise and fall of intermittent interleukin-2 therapy in HIV infection. Eur Cytokine Netw. 2010;21(3):197-201.
27. Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis. 2005;191(10):1670-1679. (Pubitemid 40656755)
28. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006;42(4):426-434. (Pubitemid 44050889)
29. Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS. 2006;20(16):2033-2041. (Pubitemid 44611056)
30. Isgrò A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis. 2008;46(12):1902-1910.
31. Delobel P, Nugeyre M-T, Cazabat M, et al. Naïve T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol. 2006;80(20):10229-10236. (Pubitemid 44522616)
32. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis. 2000;181(1):141-147. (Pubitemid 30049042)
33. Torti C, Cologni G, Uccelli MC, et al. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol. 2004;17(2):279-286. (Pubitemid 38880427)
34. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15(14):1749-1756. (Pubitemid 32939234)
35. Pido-Lopez J, Imami N, Aspinall R. Both age and gender affect thymic output: more recent thymic migrants in females than males as they age. Clin Exp Immunol. 2001;125(3):409-413. (Pubitemid 34155437)
36. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/ microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41(3):361-372. (Pubitemid 41022115)
37. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17(13):1907-1915. (Pubitemid 37070276)
38. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on haematopoiesis. Blood. 1998;91(5):1479-1495. (Pubitemid 28110310)
39. Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10 year perspective. AIDS. 2008;22(2):171-184.
40. Haas DW, Geraghty DE, Andersen J, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study. J Infect Dis. 2006;194(8):1098-1107. (Pubitemid 44547649)
41. Dornadula G, Zhang H, VanHuitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282(17):1627-1632. (Pubitemid 29513968)
42. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340(21):1614-1622. (Pubitemid 29249430)
43. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605-1613. (Pubitemid 29249429)
44. Günthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999;73(11):9404-9412. (Pubitemid 29487096)
45. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on retroviral therapy is dominated by small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80(13):6441-6457. (Pubitemid 43927447)
46. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000;6(1):76-81. (Pubitemid 30048530)
47. Petitjean G, Al Tabaa Y, Tuaillon E, et al. Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology. 2007;4:60.
48. Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16(4):460-465.
49. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009;106(23):9403-9408.
50. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7(8):e1000321.
51. McMahon D, Jones J, Wiegand A, et al. Shortcourse raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50(6):912-919.
52. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PloS ONE. 2009;4(10):e7658.
53. Doitsh G, Cavrois M, Lassen KG, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010;143(5):789-801.
54. Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 2010;24(13):1991-2000.
55. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22(15):2035-2038.
56. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2005;191(3):348-357. (Pubitemid 40139759)
57. Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005;115(11):3265-3275. (Pubitemid 41567591)
58. Lee C, Liu QH, Tomkowicz B, Yi Y, Freedman BD, Collman RG. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. J Leukoc Biol. 2003;74(5):676-682. (Pubitemid 38040343)
59. Wang JK, Kiyokawa E, Verdin E, Trono D. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A. 2000;97(1):394-399. (Pubitemid 30055842)
60. Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr. 2004;35(1):33-37. (Pubitemid 38044779)
61. Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system. J Leukoc Biol. 2010;87(6):1001-1009.
62. Camargo JF, Quinones MP, Mummidi S, et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol. 2009;182(1):171-182.
63. Wilkin T, Lalama C, Tenorio AR, et al. Maraviroc intensification for suboptimal CD4+ cell response despite sustained virologic suppression: ATCG 5256. Presented at 17th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2010; San Francisco, CA. Abstract 285.
64. Gutiérrez C, Diaz L, Hernandez-Novoa B, et al. Effect of the intensification with a CCR5 antagonist on the decay of the HIV-1 latent reservoir and residual viremia. Presented at 17th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2010; San Francisco, CA. Abstract 284.
65. Ahuja SK, Kulkarni H, Catano G, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008;14(4):413-420. (Pubitemid 351499392)
66. Vincent T, Portalès P, Baillat V, et al. The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5. J Acquir Immune Defic Syndr. 2006;43(3):377-378. (Pubitemid 44674023)
67. Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 2009;83(21):11407-11411.
68. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB. Investigators CC-iCS. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS. 2010;24(12):1857-1865.
69. Santin M, Mestre M, Shaw E, et al. Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Eur J Clin Microbiol Infect Dis. 2008;27(1):65-73. (Pubitemid 350197869)
70. Seminari E, Tinelli C, Ravasi G, et al. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res. 2010;8(3):186-193.
71. Villacres MC, Lacey SF, La Rosa C, et al. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptative immune response to cytomegalovirus. J Infect Dis. 2001;184(3):256-267. (Pubitemid 32662171)
72. Lazaro E, Coureau G, Guedj J, et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther. 2006;11(3):343-350. (Pubitemid 43823553)
73. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749-759. (Pubitemid 39299461)
74. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177-1185.
75. Fernandez S, Rosenow AA, James IR, et al. Recovery of CD4+ T cells in HIV patients with a stable virologic response to antiretroviral therapy is associated with polymorphism of interleukin-6 and central major histocompatibility complex genes. J Acquir Immune Defic Syndr. 2006;41(1):1-5. (Pubitemid 41786012)
76. Nasi M, Pinti M, Bugarini R, et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics. 2005;57(9):628-635. (Pubitemid 41457484)
77. Molloy EJ, O'Neill AJ, Grantham JJ, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood. 2003; 102(7):2653-2659. (Pubitemid 37193609)
78. Portales P, Clot J, Corbeau P. Sex difference in HIV-1 viral load due to sex difference in CCR5 expression. Ann Intern Med. 2001;134(1):81-82. (Pubitemid 32037350)
79. Puissant B, Roubinet F, Massip P, et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retroviruses. 2006;22(2):153-162. (Pubitemid 43277151)
80. Rauch A, Nolan D, Furrer H, et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis. 2008;46(12):1921-1925.
81. Du DL, Volpe DA, Grieshaber CK, Murphy MJ Jr. In vitro toxicity of 3′-azido-3′-deoxythymidine, carbovir and 2′,3′- didehydro-2′,3′-dideoxythymidine to human and murine haematopoietic progenitor cells. Br J Haematol. 1992;80(4):437-445.
82. Karrer U, Ledergerber B, Furrer H, et al. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS. 2005;19(17):1987-1994. (Pubitemid 41669023)
83. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of nonnucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet. 2006;368(9553):2125-2135. (Pubitemid 44894557)
84. Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother. 2004;54(2):503-507. (Pubitemid 39177477)
85. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatmentnaive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55(1): 39-48.
86. Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both in combination with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010;11(3):125-132.
87. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441-446. (Pubitemid 46147630)
88. Falster K, Petoumenos K, Chuah J, et al. Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune Defic Syndr. 2009;50(3):307-313.
89. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviraltreated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194(7):926-930. (Pubitemid 44454078)
90. Kimmig S, Przybylski GK, Schmidt CA, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195(6):789-794. (Pubitemid 34259723)
91. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol. 2002;76(8):3739-3747. (Pubitemid 34250538)
92. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+ CD38+ CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS. 1996;10(8):827-834.
93. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PloS ONE. 2009;4(12):e8490.
94. Brenchley JM, Price DA, Schaker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-1371. (Pubitemid 44924494)
95. Jiang Q, Li WQ, Aiello FB, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 2005;16(4-5):513-533. (Pubitemid 41022015)
96. Lévy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009;119(4):997-1007.
97. Brieu N, Portalès P, Carles MJ, Corbeau P. Interleukin-7 induces HIV type 1 R5-to-X4 switch [letter]. Blood. 2011;117(6):2073-2074.
98. Leone A, Picker LJ, Sodora DL. IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. Curr HIV Res. 2009;7(1):83-90.
99. Windmill KF, Lee VW. Effects of castration on the lymphocytes of the thymus, spleen and lymph nodes. Tissue Cell. 1998;30(1):104-111. (Pubitemid 28142348)
100. Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005;175(4):2741-2753. (Pubitemid 41113891)
101. Goldberg GL, King CG, Nejat RA, et al. Luteinizing hormone-releasing hormone enhances T cell recovery following allogenic bone marrow transplantation. J Immunol. 2009;182(9):5846-5854.
102. Min D, Panoskaltsis-Mortari A, Kuro OM, Hollander GA, Blazar BR, Weinberg KI. Sustained thymopoiesis and improvement in functional immunity by exogenous KGF administration in murine models of ageing. Blood. 2007;109(6):2529-2537. (Pubitemid 46425898)
103. Welniak LA, Sun R, Murphy WJ. The role of growth hormone in T-cell development and reconstitution. J Leukoc Biol. 2002;71(3):381-387.
104. Napolitano LA, Schmidt D, Gotway MB, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest. 2008;118(3):1085-1098. (Pubitemid 351364616)
105. Argyropoulos C, Mouzaki A. Immunosuppressive drugs in HIV disease. Curr Top Med Chem. 2006;6(16):1769-1789. (Pubitemid 44323062)
106. Archin NM, Margolis DM. Attacking latent HIV provirus: from mechanism to therapeutic strategies. Curr Opin HIV AIDS. 2006;1(2):134-140.
107. Lindkvist A, Edén A, Norström MM, et al. Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther. 2009;6:15.
108. Zhang H. Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol. 2009;41(3):451-454.
109. Hunt P, Martin J, Sinclair E, et al. Valganciclovir reduces CD8+ T cell activation among HIV-infected patients with suboptimal CD4+ T cell recovery during ART. Presented at 17th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2010; San Francisco, CA. Abstract 380.
110. Kwon HK, Lee CG, So JS, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 2010;107(5):2159-2164.